AICAR

AICAR, also known as AICA-riboside or acadesine, is a research small molecule used to study cellular energy metabolism rather than a peptide. After cellular uptake, it is phosphorylated to ZMP, an AMP-mimetic nucleotide that can activate AMPK and shift metabolism away from energy-consuming synthesis toward glucose and fatty-acid handling ^[1]. Early cell and animal studies showed AMPK activation, reduced malonyl-CoA, increased fatty-acid oxidation, and greater skeletal-muscle glucose uptake ^[1][2]. In mice, chronic AICAR changed oxidative muscle gene programs and increased treadmill endurance, making it a widely cited exercise-mimetic research compound ^[5]. Human evidence is narrower: acute IV studies in healthy men and men with type 2 diabetes reported effects on muscle glucose uptake, hepatic glucose output, and lipolysis, but these were controlled experimental infusions rather than consumer-use trials ^[3][4]. Acadesine was also studied around CABG surgery; the large RED-CABG phase 3 trial was stopped for futility and did not improve its primary clinical outcome ^[6][7]. AICAR should be described as investigational, non-approved, and prohibited in sport ^[8].

AMPK and Cellular Energy Signaling

AICAR is mainly studied as an AMPK-pathway research tool. In cells, AICAR is converted to ZMP, an AMP-like nucleotide that can promote AMPK activation and downstream phosphorylation of metabolic targets ^[1]. This makes it useful for studying energy-sensing pathways, but it should not be framed as a general wellness compound.

Glucose and Fatty-Acid Metabolism Research

Preclinical skeletal-muscle work found that AICAR activated AMPK, reduced malonyl-CoA, increased fatty-acid oxidation, and increased glucose uptake in rat muscle models ^[2]. Human infusion studies are more limited but suggest acute metabolic effects: AICAR increased skeletal-muscle 2-deoxyglucose uptake in healthy men and reduced hepatic glucose output in a small study of men with type 2 diabetes ^[3][4].

Exercise-Mimetic Models

In mice, AICAR treatment induced oxidative muscle gene programs and improved treadmill endurance, supporting its role as an exercise mimetic in preclinical research ^[5]. These findings should be presented as animal evidence only; they do not establish performance, body-composition, or endurance benefits in humans.

Cardiometabolic Translation Limits

Acadesine was tested clinically as an adenosine-regulating/cardioprotective agent in CABG surgery, but the large RED-CABG trial was stopped for futility and did not reduce the primary composite outcome ^[6][7]. This limits any claim that AICAR has proven clinical cardiovascular benefit.

Investigational and Non-Approved Status

AICAR/acadesine should be treated as investigational. The largest phase 3 acadesine trial, RED-CABG, was terminated after futility analysis and did not show benefit on all-cause mortality, nonfatal stroke, or severe left-ventricular dysfunction after CABG surgery ^[6][7]. No approved consumer or general therapeutic use should be implied.

Human Evidence Comes From IV Research Settings

The available human metabolic studies used controlled IV infusion protocols with glucose tracers, biopsies, and clinical monitoring ^[3][4]. These studies do not establish safe self-administration, long-term dosing, or benefits for healthy users.

Metabolic and Medical Cautions

AICAR affects glucose and lipid metabolism in experimental settings, including hepatic glucose output, skeletal-muscle glucose uptake, and lipolysis markers ^[3][4]. People with diabetes, cardiovascular disease, kidney/liver issues, gout history, or medication interactions would be outside any reasonable low-risk assumption; RED-CABG also excluded several higher-risk clinical categories ^[7].

Sport and Anti-Doping Status

AICAR is prohibited in sport as an AMPK-activating metabolic modulator on the WADA Prohibited List ^[8]. Athletes subject to anti-doping rules should treat AICAR as banned.